The U.S. Department of Health and Human Services announced on Monday that the first government‑funded clinical trials of ibogaine are moving forward. The initiative follows an April executive order by President Trump that earmarked $50 million for federal research into the psychedelic compound.
Why ibogaine?
Ibogaine is derived from the roots of the African shrub iboga and is currently classified as a Schedule I controlled substance. Despite its illegal status, many military veterans have traveled abroad seeking relief from trauma and opioid addiction, prompting federal officials to examine its therapeutic potential under controlled conditions.
Trial design and safety focus
The Advanced Research Projects Agency for Health (ARPA‑H) and the National Institute on Drug Abuse will fund early‑stage studies. Participants will receive a single, gradual dose capped at 10 milligrams per kilogram and will be monitored continuously in a hospital setting for up to 36 hours to detect any cardiac irregularities.
“Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches,” said Michael Davis, director of the FDA’s Center for Drug Evaluation and Research. Davis emphasized that the agency will prioritize patient safety throughout the trials.
Regulatory safeguards
The Food and Drug Administration has warned that ibogaine carries significant health risks, including life‑threatening irregular heart rhythms and potential brain toxicity. To address these concerns, the FDA opened a public docket seeking feedback on trial design, dose selection, patient eligibility, safety monitoring, study‑stopping rules, and oversight. Comments are accepted through November 20.
These public inputs will help shape the agency’s oversight framework and could inform future applications to test ibibaine in humans.
Broader context
The move reflects a growing bipartisan interest in exploring psychedelic therapies for conditions that have resisted conventional treatment. While the Trump administration’s funding signals a commitment to innovative medical research, it also underscores the need for stringent safety standards, a balance that the FDA is actively pursuing.
Veterans and addiction specialists have welcomed the federal backing, noting that rigorous, government‑sponsored trials could provide the data needed to assess ibogaine’s efficacy and safety, potentially opening new pathways for patients who have exhausted other options.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
